The third domestic "Adamo single resistance" was approved for listing! The price of the original study Merle increased 18 times in ten years.

Guide: Thyda Adamo single anti-single resistance approved for listing; AbbVie was summoned by the government for its high price! On September 3, the State Drug Administration issued a batch of drug approval documents to be received information, Xinda Bio "Adamo single anti-injection" ranked first, meaning that Xinda Bio "Adamo single anti-injection" with priority review qualification successfully and quickly approved the market, becoming the third domestic Adamo single anti-biosynthic drug.
Adamo monoantigen injection is the world's first approved all-human source anti-tumor necrotic cause ɑ (TNF-ɑ) monoclonal antibody that specifically binds to soluble human TNF-ɑ and blocks its interaction with cell surface TNF ligands p55 and p75, effectively blocking the inflammatory effects of TNF-ɑ.
Adamu single antigen research drug (commodity name: Shumeile) developed by AbbVie, Shumeile in China was approved for 3 adaptive diseases, in addition, march 28, 2019 CDE released china's second batch of clinically urgent need for new drugs abroad XiuMeile was included in the list for the treatment of vine membraneitis.
2018 global sales of $20.5 billion, ranking first among the world's best-selling drugs for the seventh consecutive year.
according to the world's best-selling drug sales data show that in 2019, Adamo single anti-global sales of 137.4 billion yuan, of which the original research accounted for 132 billion yuan.
Adamu single anti-ocgen global sales chart according to pharmaceutical data show that up to now, including Thyda biological Adamo single anti-injection, a total of 3 domestic Adamo single anti-biosygenic drugs approved for the market, the remaining two are November 7, 2019, Baiotai listed Greli, December 6, 2019 Haizheng Pharmaceuticals listed an jianning.
according to the drug zhi winning data show that Baiotai and Haizheng Pharmaceuticals the lowest winning bid price of this variety is 1150 yuan, of which Baiotai winning area has 14, Haizheng Pharmaceuticals has 13.
addition, the 2020 Baiotai semi-annual report shows that the first half of Greeley's domestic sales of 48.7864 million yuan.
's Adamo single anti-biosychable drug market will increase to 4.7 billion yuan in 2023 and reach 11.5 billion yuan by 2030, according to the Adamu single-anti-bid enterprise dimension analysis Tu baiotai prospecto.
market demand is huge, now with the domestic bio-similar drugs on the market, Adamo single resistance prices are expected to be significantly reduced, and in 2019 Shumeile through negotiations into the national health insurance, to solve the pain points of patients.
worth mentioning is that AbbVie was recently summoned by the government for high pricing by "drug king" Shumeile.
U.S. government noted that in the 10 years from 2009 to 2019, AbbVie raised the price of the ride 18 times.
years, Shumeile as the "King of Drugs" has been the world's best-selling drug.
Despite the approval of a variety of biosimilars, AbbVie has been using various legal means to protect the patent rights to the "money tree" drug to reduce the market space for generic drugs.
According to the data of pharmaceutical intelligence, the current domestic Adamo single anti-biological similar drugs in addition to Baiotai, Haizheng Pharmaceuticals, Xinda Biological three enterprises were approved for listing, Fuhong Hanxuan, United Creatures, Zhengda Tianqing this variety is also on the way to the market, and Fuhong Hanyu varieties have been included in the priority review sequence, approved for listing also refers to the day to wait.
data sources: pharmaceutical intelligence data, enterprise announcements and other public data sources: pharmaceutical intelligence network, the State Drug Administration, Sina pharmaceutical, corporate announcements and so on.